Shopping Cart
- Remove All
- Your shopping cart is currently empty
Ebronucimab (AK102) is an IgG1 antibody targeting PCSK9 that lowers LDL-C, TC, Non-HDL-C, and ApoB, and raises, HDL-C and Apo A-I for the treatment of primary hypercholesterolemia and mixed hyperlipidemia and heterozygous familial hypercholesterolemia (HeFH).
Pack Size | Price | Availability | Quantity |
---|---|---|---|
1 mg | $232 | In Stock | |
5 mg | $578 | In Stock | |
10 mg | $828 | In Stock | |
25 mg | $1,260 | In Stock | |
50 mg | $1,680 | In Stock |
Description | Ebronucimab (AK102) is an IgG1 antibody targeting PCSK9 that lowers LDL-C, TC, Non-HDL-C, and ApoB, and raises, HDL-C and Apo A-I for the treatment of primary hypercholesterolemia and mixed hyperlipidemia and heterozygous familial hypercholesterolemia (HeFH). |
In vivo | In a multi-center randomized controlled trial conducted among Chinese patients with hypercholesterolemia, Ebronucimab, administered at 450 mg every 4 weeks or 150 mg every 2 weeks, significantly reduced serum LDL-C levels over 12 weeks (by approximately 59.13% and 60.43%, respectively), and showed high LDL-C goal achievement rates across different cardiovascular risk categories[1]. |
Alias | AK102, AK 102 |
Cas No. | 2304800-90-4 |
Storage | store at low temperature | store at -20°C | Shipping with blue ice. |
Copyright © 2015-2025 TargetMol Chemicals Inc. All Rights Reserved.